YHLO launched its latest iFlash integrated system at CMEF, reaching new milestone with our persistence in R&D
October 13, 2021, Shenzhen, China, YHLO grandly showed up at the China International Medical Equipment Fair(CMEF), brought another new high-end product iFlash 9000 to the spotlight.
CMEF is recognized as the largest scale and most well-know expo fair in China for MedTech, it attracts over 100,000 professional visitors to participate every year. Annually numbers of enterprises, dealers and agencies , medical doctors and experts, etc. are joining together in this big event from all over the world.
In the autumn season of 2021, CMEF hosted in Shenzhen, where YHLO’s headquarters is based, the new member of YHLO iFlash family, iFlash 9000 was released and showcased at the exhibition site. Based on the very strong R&D capability, YHLO launched its first CLIA instrument in 2016, the iFlash 3000, which was China’s first high throughput CLIA analyzer. Since that, YHLO launched iFlash 1800 (bench-top CLIA) in 2017, iModules Modular System in 2019, iFlash 1200 in 2021, and developed over 120 assays for chemiluminescent immunoassay platform.
With up to 600 tests/hour’s throughput, iFlash 9000 is an ideal CLIA for the laboratories and hospitals with large testing volume . And it also supports modular expansion, up to 4 units can be integrated, which can boost the analysis throughput up to 2400 tests/hour. Plus, the excellent performance, flexible sample workflow and highly accurate system can greatly improve efficiency, productivity and quality.
With the mission of “Focus on healthcare, better life with technology”, YHLO will continue to provide reliable, high-quality healthcare innovations and services worldwide to improve human well-being.
Attachments:
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
